The global demand for COVID-19 Therapeutics Market is presumed to reach the market size of nearly USD 74.96 BN by 2030 from USD 33.92 BN in 2022 with a CAGR of 10.42% under the study period 2023 - 2030.
COVID-19 therapeutics refer to the drugs and therapies used for the treatment of COVID-19, the respiratory illness caused by the SARS-CoV-2 virus. COVID-19 therapeutics include antiviral drugs, immunomodulatory drugs, and monoclonal antibodies, among others. The goal of COVID-19 therapeutics is to reduce the severity of symptoms, prevent complications, and improve the overall outcomes of patients with COVID-19.
The COVID-19 pandemic has resulted in high demand for COVID-19 therapeutics due to the increasing number of cases and the need for effective treatment options. Governments worldwide are providing funding and support to accelerate the development and availability of COVID-19 therapeutics. This has led to increased investment in research and development, as well as regulatory support for the expedited approval of potential therapies. The emergence of new variants has led to an increased need for COVID-19 therapeutics that can effectively treat these new strains of the virus. New therapeutic targets are being identified as the scientific community learns more about COVID-19, leading to the development of novel therapies that may be more effective in treating the disease. Collaboration among healthcare organizations, including pharmaceutical companies and research institutions, is driving the development and availability of COVID-19 therapeutics.
The research report covers Porter’s Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of covid-19 therapeutics. The growth and trends of covid-19 therapeutics industry provide a holistic approach to this study.
This section of the covid-19 therapeutics market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Drug Class
- Monoclonal Antibodies
- Kinase Inhibitors
- Others (Anti-Inflammatory Drugs, Convalescent Plasma, Others)
By Route Of Administration
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
This section covers the regional outlook, which accentuates current and future demand for the COVID-19 Therapeutics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
Global COVID-19 Therapeutics Market Share by Region (Representative Graph)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the covid-19 therapeutics market include F.Hoffmann-La Roche Ltd, Gilead Sciences Inc., Eli Lilly and Company, Pfizer Inc., Merck & Co. Inc., GSK plc, Celltrion Healthcare Co. Ltd, Sorrento Therapeutics, AstraZeneca plc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.